The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma
Open accessAbstract
Summary: Chondroitin sulfate proteoglycan 4 (CSPG4), a transmembrane proteoglycan originally identified as a highly immunogenic tumor antigen on the surface of melanoma cells, is associated with melanoma tumor formation and poor prognosis in certain melanomas and several other tumor types. The complex mechanisms by which CSPG4 affects melanoma progression have started to be defined, in particular the association with other cell surface proteins and receptor tyrosine kinases (RTKs) and its central role in modulating the function of these proteins. CSPG4 is essential to the growth of melanoma tumors through its modulation of integrin function and enhanced growth factor receptor‐regulated pathways including sustained activation of ERK 1,2. This activation of integrin, RTK, and ERK1,2 function by CSPG4 modulates numerous aspects of tumor progression. CSPG4 expression has further been correlated to resistance of melanoma to conventional chemotherapeutics. This review outlines recent advances in our understanding of CSPG4‐associated cell signaling, describing the central role it plays in melanoma tumor cell growth, motility, and survival, and explores how modifying CSPG4 function and protein–protein interactions may provide us with novel combinatorial therapies for the treatment of advanced melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The NG2 proteoglycan: Past insights and future prospects
Stallcup, W. B. (2002) · Journal of Neurocytology · doi:10.1023/a:1025731428581 · Cited by 296
Cited by
Proteoglycan form and function: A comprehensive nomenclature of proteoglycans
Iozzo, R. V., & Schaefer, L. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.02.003 · Cited by 1,263
Wang, J., Zhou, X., Yu, P., Yao, J., Guo, P., Xu, Q., Zhao, Y., Wang, G., Li, Q., Zhu, X., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00886-2 · Cited by 28
Metadata
- Authors
- Price, M. A., Colvin Wanshura, L. E., Yang, J., Carlson, J., Xiang, B., Li, G., Ferrone, S., Dudek, A. Z., Turley, E. A., & McCarthy, J. B.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2011-11-22
- Volume
- 24
- Issue
- 6
- Pages
- 1148-1157
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W2147233186
- Cited by
- 202
- References
- 1
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. https://app.cochat.ai/papers/10.1111/j.1755-148x.2011.00929.x
- The paper
- Price, M. A., Colvin Wanshura, L. E., Yang, J., Carlson, J., Xiang, B., Li, G., Ferrone, S., Dudek, A. Z., Turley, E. A., & McCarthy, J. B. (2011). CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell & Melanoma Research. https://doi.org/10.1111/j.1755-148x.2011.00929.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.